☆ 4.5 Article

Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study

ANNALS OF INTENSIVE CARE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Michele Merli et al.

Summary: A study analyzed data from CLL patients with COVID-19 in Italy and found that male sex, age over 70, recent CLL treatment, and COVID-19 severity were independently associated with poor survival. The study revealed a dismal COVID-related outcome in a significant fraction of CLL patients.

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Immunology

Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019

Jeremy A. W. Gold et al.

Summary: We examined the incidence of invasive fungal infections (IFIs) within the first year of small molecule kinase inhibitor (SMKI) therapy based on administrative data analysis. The occurrence of IFIs ranged from 0.0% to 10.6% depending on the specific SMKI used, with midostaurin showing the highest incidence. Among the 1286 patients treated with ibrutinib, 38 individuals (3.0%) developed IFIs.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Oncology

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Matt Shirley

Summary: The development of Bruton tyrosine kinase (BTK) inhibitors has dramatically improved the management of B-cell malignancies, with more advanced second and third-generation agents providing better tolerability and treatment options. These inhibitors have shown strong activity in various B-cell malignancies and are generally well-tolerated, with manageable adverse events through dosage adjustment. This review article summarizes the evidence supporting the role of BTK inhibitors in the management of B-cell malignancies, highlighting their differences and benefits.

TARGETED ONCOLOGY (2022)

添加到收藏夹

Article Immunology

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

Steven E. Coutre et al.

Summary: Ibrutinib did not improve the proportion of hospitalized patients with severe COVID-19 who were alive and without respiratory failure through day 28. Ibrutinib had a manageable safety profile, similar to placebo.

OPEN FORUM INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Hematology

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Paul M. Barr et al.

Summary: This study reports long-term follow-up data from the RESONATE-2 phase 3 study of ibrutinib in previously untreated CLL patients. The results show that ibrutinib provides sustained benefit in terms of progression-free survival and overall survival, even in patients with high-risk genomic features.

BLOOD ADVANCES (2022)

添加到收藏夹

Article

New Directions for Mantle Cell Lymphoma in 2022

Anita Kumar et al.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)

添加到收藏夹

Review Cell Biology

BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy

Michael C. McGee et al.

Summary: Bruton's tyrosine kinase (BTK) signaling plays a crucial role in COVID-19 immunopathology and may be a potential target for treatment. Consideration should be given to the potential off target effects of BTK inhibitors on T cell function when studying their therapeutic effects.

JOURNAL OF LEUKOCYTE BIOLOGY (2021)

添加到收藏夹

Article Oncology

Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

B. Eichhorst et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

Michael Hallek et al.

Summary: Chronic lymphocytic leukemia is a common type of leukemia in elderly patients, diagnosed through blood tests and immunophenotyping. Treatment is determined based on disease activity and stage, with different genetic and biological markers providing prognostic information.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management

Morie A. Gertz

Summary: WM is a lymphoma with IgM monoclonal protein, diagnosed by presence of clonal lymphoplasmacytic cells and MYD88 gene mutation. Predictive characteristics for outcomes include age, hemoglobin level, platelet count, beta(2) microglobulin, LDH, and monoclonal IgM concentrations. Treatment options include rituximab and bendamustine as preferred induction, with various other agents showing activity in relapsed cases of refractory disease.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia

Isabelle G. Solman et al.

Summary: This study evaluated the long-term immunophenotypic changes in immune cell subsets of chronic lymphocytic leukemia patients treated with ibrutinib. The results showed that ibrutinib had positive effects on immune cells over a 4-year treatment period, improving clinical outcomes. The normalization of adaptive and innate immune cell populations suggests that long-term ibrutinib treatment may mediate restoration of immunity.

LEUKEMIA RESEARCH (2021)

添加到收藏夹

Article Oncology

Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study

Maria Stefania Infante et al.

Summary: This study analyzed infectious complications in patients with lymphoproliferative diseases treated with targeted therapies. Severe infections occurred in 23% of patients, predominantly bacterial in nature, with a small percentage attributed to invasive fungal infections. Risk factors for severe infection included severe lymphopenia, combined targeted treatment, and previous rituximab usage. Infection-related mortality was 6%, and antimicrobial prophylaxis should be considered in high-risk cases.

CANCER MEDICINE (2021)

添加到收藏夹

Review Immunology

The role of Bruton's tyrosine kinase in the immune system and disease

Charlotte McDonald et al.

Summary: BTK, a TEC kinase with a critical role in B-cell biology, has gained momentum as a therapeutic target in various hematological malignancies. It plays a significant role not only in lymphoproliferative disorders but also in autoimmune diseases and response to infection. Developing novel, more specific BTK inhibitors is crucial to address the rising levels of resistance and meet the unmet treatment needs of various diseases.

IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

John C. Byrd et al.

Summary: In this study, acalabrutinib was found to be noninferior to ibrutinib in terms of progression-free survival in patients with CLL, with a lower incidence of cardiovascular adverse events. This suggests that acalabrutinib may be a more tolerable option for continuous therapy in this patient population.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus

Damien Blez et al.

HAEMATOLOGICA (2020)

添加到收藏夹

Article Immunology

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

J. Peter Donnelly et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Hematology

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study

Constantine S. Tam et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato et al.

BLOOD (2020)

添加到收藏夹

Article Infectious Diseases

National Early Warning Score (NEWS) as Prognostic Triage Tool for Septic Patients

Abdulaziz Almutary et al.

INFECTION AND DRUG RESISTANCE (2020)

添加到收藏夹

Letter Oncology

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

Kerry A. Rogers et al.

LEUKEMIA (2019)

添加到收藏夹

Article Hematology

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Talha Munir et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Review Hematology

How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia

Deborah M. Stephens et al.

BLOOD (2019)

添加到收藏夹

Article Hematology

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

David Ghez et al.

BLOOD (2018)

添加到收藏夹

Letter Hematology

Ibrutinib blocks Btk-dependent NF-κB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis

Amelia Bercusson et al.

BLOOD (2018)

添加到收藏夹

Article Immunology

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

Tilly Varughese et al.

CLINICAL INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Oncology

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Susan O'Brien et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)

添加到收藏夹

Review Hematology

Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies

Benjamin F. Tillman et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2018)

添加到收藏夹

Editorial Material Hematology

Ibrutinib and Aspergillus: a Btk-targeted risk

Jennifer A. Woyach

BLOOD (2018)

添加到收藏夹

Article Medicine, General & Internal

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

J. A. Woyach et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Immunology

Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways

Georgios Chamilos et al.

CLINICAL INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Immunology

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia

Qingsong Yin et al.

JOURNAL OF IMMUNOLOGY (2017)

添加到收藏夹

Article Oncology

Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios A. Dimopoulos et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Michail S. Lionakis et al.

CANCER CELL (2017)

添加到收藏夹

Review Hematology

Targeted therapies for CLL: Practical issues with the changing treatment paradigm

Nitin Jain et al.

BLOOD REVIEWS (2016)

添加到收藏夹

Article Medicine, General & Internal

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Hematology

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Clare Sun et al.

BLOOD (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus

Susanne Herbst et al.

EMBO MOLECULAR MEDICINE (2015)

添加到收藏夹

Article Oncology

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks et al.

JAMA ONCOLOGY (2015)

添加到收藏夹

Letter Hematology

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

Holbrook E. Kohrt et al.

BLOOD (2014)

添加到收藏夹

Article Medicine, General & Internal

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

J. C. Byrd et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Oncology

Outcomes of Critically Ill Patients With Hematologic Malignancies: Prospective Multicenter Data From France and Belgium-A Groupe de Recherche Respiratoire en Reanimation Onco-Hematologique Study

Elie Azoulay et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Hematology

Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses

A Mangla et al.

BLOOD (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.